Maha Katabi, PhD, CFA

Maha Katabi, PhD, CFA

General Partner

Maha Katabi is a General Partner of Sofinnova Investments. She is an experienced investor with over two decades of managing public and private biotech companies through bull and bear markets. She is currently a board member of Aerovate (AVTE), Aiolos, Quanta, RayzeBio (RYZB), Star ,and Vera (VERA). She previously was a board member of Amplyx (acquired by Pfizer), Gyroscope (acquired by Novartis) and Northsea.

Prior to joining Sofinnova in 2019, Maha was Managing Partner of Oxalis Capital and prior to that was Partner at Sectoral Asset Management. There, she formed and led a dedicated team to manage investments in private companies and was a Portfolio Manager for a family of funds investing in small cap healthcare companies. Maha co-invested with Sofinnova in multiple companies: Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND), and Trius Therapeutics (TSRX-acquired by Cubist). Earlier in her career, she worked as an associate and principal investing in seed and early stage biotech at T2C2/Bio and Ventures West.

Most recently Fierce Pharma named Maha one of 2023’s Fiercest Women in Life Sciences. Maha serves as an advisor to amplifyHERscience, a Yale Ventures initiative. She is Board Chair of Exactis Innovation, a not for profit research network for precision oncology operating a data analytics platform to provide real world evidence data to clinical researchers and payors.

Maha received a Ph.D. in Pharmacology and a B.Sc. in Biology at McGill University and was awarded a Cancer Research Society scholarship. She is a CFA charterholder.

Active Companies

Alumni Companies